VJHemOnc is committed to improving our service to you

EHA 2019 | Molecular MRD detection in AML

VJHemOnc is committed to improving our service to you

Peter Valk

In this video Peter Valk, PhD, from the Erasmus University Medical Center, Rotterdam, Netherlands, discusses precision medicine in acute myeloid leukemia (AML), namely biomarkers for early detection and molecular measurable residual disease detection. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter